Literature DB >> 21325759

Clinical features of lymphangioleiomyomatosis complicated by renal angiomyolipomas.

Yoshiko Mizushina1, Masashi Bando, Tatsuya Hosono, Naoko Mato, Takakiyo Nakaya, Yoshikazu Ishii, Hideaki Yamasawa, Yukihiko Sugiyama.   

Abstract

OBJECTIVE: Renal angiomyolipomas (R-AMLs) are major complications of lymphangioleiomyomatosis (LAM). The objective of this study was to better understand the influence of R-AMLs in patients with LAM on the prognosis and other clinical factors related to respiration, and to investigate the management of R-AMLs in patients with LAM. PATIENTS AND METHODS: We retrospectively investigated the clinical features of 7 patients with LAM [4 were TSC (Tuberous sclerosis complex)-LAM and 3 were S (sporadic)-LAM] complicated by R-AMLs admitted to our hospital from 1997 to 2008.
RESULTS: All patients were females and the mean age at diagnosis of LAM was 40.7 years (31.7 years for TSC-LAM and 52.7 years for S-LAM). Although 5 patients had symptoms related to R-AMLs, only 1 patient experienced symptoms related to R-AMLs at the time of diagnosis. Five patients had bilateral and 2 patients had unilateral R-AMLs. R-AMLs ruptured in 4 cases (3 patients were TSC-LAM) including 2 patients in whom they ruptured bilaterally, and who underwent bilateral nephrectomy. In 1 case, unilateral R-AMLs grew larger and appeared on the other side during the follow-up period.
CONCLUSION: Although only rare cases of LAM show symptoms related to R-AMLs initially, R-AMLs are a notable complication. To avoid nephrectomy, R-AMLs should be diagnosed when they are small and should be followed up carefully by periodic echograms or CT scans.
© 2011 The Japanese Society of Internal Medicine

Entities:  

Mesh:

Year:  2011        PMID: 21325759     DOI: 10.2169/internalmedicine.50.3558

Source DB:  PubMed          Journal:  Intern Med        ISSN: 0918-2918            Impact factor:   1.271


  1 in total

1.  Lymphangioleiomyomatosis Presenting with Perirenal Hemorrhage.

Authors:  S Dekeyzer; N Peters; P Smeets; P De Visschere; K Decaestecker; R Gosselin
Journal:  J Belg Soc Radiol       Date:  2015-09-15       Impact factor: 1.894

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.